Interferon-α: Regulatory effects on cell cycle and angiogenesis

Neuroendocrinology

Volumn 80, Issue SUPPL. 1, 2004, Pages 85-93

  Rosewicz, Stefan ^a   Detjen, Katharina ^a   Scholz, Arne ^a   Von Marschall, Z ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; Interferon ; Neuroendocrine tumor disease

Indexed keywords

CYCLIN B; PROTEIN KINASE; RECOMBINANT ALPHA INTERFERON; STAT PROTEIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR DIFFERENTIATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTERFERON-ALPHA; JANUS KINASE 1; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTORS, INTERFERON; RECEPTORS, SOMATOSTATIN; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TYK2 KINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 6044276873     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080748     Document Type: Conference Paper

References (29)

1. Creutzfeldt W: Endocrine tumors of the pancreas; in Arquila E, Volks BW (eds): The Diabetic Pancreas. New York, Plenum, 1985, pp 534-563.
2. Wiedenmann B, John M, Ahnert-Hilger G, Riecken EO: Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J Mol Med 1998;76:637-647.
3. Jensen RT: Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000;12:368-377.
4. Faiss S, Pape UF, Böhmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-2696.
5. Arnold R, Simon B, Wied M: Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review. Digestion 2000;62(suppl 1):84-91.
6. Öberg K: State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000;44:3-12.
7. Sangfelt O, Erickson S, Grander D: Mechanisms of interferon-induced cell cycle arrest. Front Biosci 2000;5:D479-D487.
8. Gutterman JU: Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91:1198-1205.
9. Grander D, Einhorn S: Interferon and malignant disease - How does it work and why doesn't it always? Acta Oncol 1998;37:331-338.
10. Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, Wiedenmann B, Rosewicz S: Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000;118:735-748.
11. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Öberg K, Wiedenmann B, Höcker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448.
12. Schäfer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Höcker M: Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 2003;278:8190-8198.
13. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
14. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G: Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997;15:669-676.
15. Philipsen S, Suske G: A tale of three fingers: The family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999;27:2991-3000.
16. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D: Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997;8:343-352.
17. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, Kojiro M: Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:1708-1717.
18. Garrison JI, Berens ME, Shapiro JR, Treasurywala S, Floyd-Smith G: Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines. J Neurooncol 1996;30:213-223.
19. Lundblad D, Lundgren E: Block of glioma cell line in S by interferon. Int J Cancer 1981;27:749-754.
20. Preisler HD, Gopal V, Banavali SD, Finke D, Bokari SA: Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer Res 1992;52:4090-4095.
21. Ohwada S, Kobayashi I, Maemura M, Satoh Y, Ogawa T, Iino Y, Morishita Y: Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer Lett 1996;110:149-154.
22. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J: Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997;17:355-367.
23. Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
25. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-579.
26. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
27. Majello B, De Luca P, Lania L: Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. J Biol Chem 1997;272:4021-4026.
28. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S: Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem 2000;275:22769-22779.
29. Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, Davis DW, Fidler IJ: Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001;3:154-164.